A Phase 1 interventional study of SK-0403 in Type 2 Diabetes Mellitus, sponsored by Kowa Research Institute, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-02-10.
Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States — 343 open to participants now, 478 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.
Among the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 2,234th largest by planned enrollment of the 2,957 interventional ones that give a count, is one of 167 that started in 2010, is one of 383 in phase 1, and was the 944th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →343 of the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Puerto Rico
Ages 18+
University of Minnesota · Sites in United States
Ages 30–75
Pfizer · Sites in United States
Ages 18+
Rahul Sachdeva · Sites in United States
Ages 18+ · Healthy volunteers
Amgen · Sites in United States, Canada
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,304 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 423 · Phase 2 464 · Phase 3 613 · Phase 4 300
First in 1976; this study’s year is marked. 167 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 90 across the 2,957 interventional studies, 128 across the 336 observational. Of the 2,648 that completed or were terminated, 1,165 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
1,486 of 3,304 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kowa Research Institute, Inc., one of the names counted as Kowa Company, Ltd.. Under that name alone:
Kowa Research Institute, Inc. is the lead sponsor of 47 studies on the registry; 1 is open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 9 (45%) have results posted.
Kowa Company, Ltd. has 5 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
187 of the studies in Diabetes Mellitus, Type 2 with a site in United States that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06731075Phase 3Oramed, Ltd.A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus. | 2027-04-25 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07817251Phase 3Novo Nordisk A/SResearch Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | 2027-06-09 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
Add all 187 to your calendar (.ics) → With an account.
Among the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1, multicenter, open label, single dose study. A total of 30 subjects are planned (5 groups of 6 subjects each.)
This is a Phase 1, multicenter, open label, single dose study. A total of 30 subjects are planned (5 groups of 6 subjects each) as follows:
Group A: Subjects with ESRD who are receiving hemodialysis treatment
Group B: Subjects with severe renal impairment
Group C: Subjects with moderate renal impairment
Group D: Subjects with mild renal impairment
Group E: Healthy subjects
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with end stage renal disease (ESRD) who are receiving hemodialysis treatment
Drug: SK-0403
Subjects with severe renal impairment
Drug: SK-0403
Subjects with moderate renal impairment
Drug: SK-0403
Subjects with mild renal impairment
Drug: SK-0403
Healthy subjects
Drug: SK-0403
SK-0403 400 mg
The primary objective is to determine the effect of renal insufficiency on the pharmacokinetics of a single 400 mg dose of SK 0403.
Time frame: 72 Hours
The secondary objective is to determine the safety and tolerability of a single 400 mg dose of SK 0403 in subjects with renal insufficiency.
Time frame: 72 Hours
The record gives a start of May 2010, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anagliptin
Kowa Research Institute, Inc. →